Macquarie Group Ltd. Trims Stake in Heska Corp (HSKA)

Macquarie Group Ltd. cut its stake in shares of Heska Corp (NASDAQ:HSKA) by 5.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,592 shares of the medical research company’s stock after selling 147 shares during the quarter. Macquarie Group Ltd.’s holdings in Heska were worth $223,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. We Are One Seven LLC purchased a new position in shares of Heska during the fourth quarter worth approximately $86,000. LS Investment Advisors LLC increased its position in shares of Heska by 30.1% during the fourth quarter. LS Investment Advisors LLC now owns 1,133 shares of the medical research company’s stock worth $98,000 after acquiring an additional 262 shares during the period. Bank of Montreal Can increased its position in shares of Heska by 11.7% during the fourth quarter. Bank of Montreal Can now owns 1,876 shares of the medical research company’s stock worth $162,000 after acquiring an additional 196 shares during the period. Municipal Employees Retirement System of Michigan purchased a new position in shares of Heska during the fourth quarter worth approximately $168,000. Finally, Virtu Financial LLC purchased a new position in shares of Heska during the third quarter worth approximately $223,000. 84.15% of the stock is currently owned by institutional investors and hedge funds.

Shares of HSKA stock opened at $74.66 on Wednesday. The company has a market cap of $587.40 million, a P/E ratio of 52.69 and a beta of 0.80. Heska Corp has a 52-week low of $71.60 and a 52-week high of $114.50.

Heska (NASDAQ:HSKA) last issued its quarterly earnings data on Tuesday, February 26th. The medical research company reported $0.46 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.75 by ($0.29). The business had revenue of $34.06 million for the quarter, compared to analysts’ expectations of $40.59 million. Heska had a net margin of 4.59% and a return on equity of 9.87%.

In related news, COO Jason A. Napolitano sold 7,500 shares of Heska stock in a transaction that occurred on Monday, February 4th. The shares were sold at an average price of $100.00, for a total transaction of $750,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have sold 22,500 shares of company stock worth $2,199,825. 14.00% of the stock is currently owned by corporate insiders.

A number of equities analysts have recently commented on HSKA shares. Zacks Investment Research raised shares of Heska from a “hold” rating to a “buy” rating and set a $101.00 target price on the stock in a research report on Thursday, January 10th. Canaccord Genuity reissued a “buy” rating and set a $118.00 price objective on shares of Heska in a report on Wednesday, February 20th. Benchmark lowered shares of Heska from a “buy” rating to a “hold” rating in a report on Wednesday, February 27th. BidaskClub raised shares of Heska from a “sell” rating to a “hold” rating in a report on Wednesday, March 27th. Finally, Sidoti lowered shares of Heska from a “buy” rating to a “neutral” rating in a report on Tuesday, February 26th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $109.00.

TRADEMARK VIOLATION NOTICE: “Macquarie Group Ltd. Trims Stake in Heska Corp (HSKA)” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.com-unik.info/2019/04/17/macquarie-group-ltd-trims-stake-in-heska-corp-hska.html.

Heska Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Read More: Why do companies issue convertible shares?

Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).

Institutional Ownership by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit